ASX health stocks today: AdAlta (ASX:1AD) leads after successful Phase I study
Health & Biotech
Health & Biotech
Link copied to
Health stock AdAlta (ASX:1AD) leads the ASX health care index on a good morning which saw it rise by 1.2% compared to the broader index which fell by 1.2% at the halfway mark.
There were some positive announcements coming out of small cap ASX health stocks this morning, which moved share prices.
The best performing ASX health stock today is that of AdAlta (ASX:1AD), which rose by almost 4% after announcing it will progress into efficacy studies for its inhaled version of AD-214 to treat
Idiopathic Pulmonary Fibrosis (IPF).
The company has just successfully completed Phase I clinical studies for the first cohort of healthy volunteers, who received multiple doses at 5 mg/kg via intravenous administration.
Data from the Phase I study suggested that AD-214 molecule fully engages its target receptor in humans, with no dose limiting safety issues.
The diagnostic imaging specialist announced it has licensed its eUnity universal viewing solution to Advocate Aurora Health. The licence contract is valued at $4.3 million, with Mach7 expected to recognise $1.5 million – $1.7 million in FY22, with the remainder being recognised evenly from FY23 – FY27.
The company signed a distribution deal with Malaysia-based Biomed Global for the distribution of the EuGeni Reader platform and SARS-CoV-2 Antigen Rapid Diagnostic Test (RDT).
According to AnteoTech, Biomed Global is one of the most respected brands in the biomedical and life sciences industry in Malaysia and Singapore.
AnteoTech has been working on evaluating the possibility of detecting the SARS-CoV-2 antigen taken from sample sites, offering a more comfortable method of testing for the patient.
The company says that following strong interest in the EuGeni COVID-19 RDT platform from a number of Indian companies, the opportunity to conduct an extensive clinical evaluation arose, allowing it to further assess the performance of the EuGeni COVID-19 RDT using live patient samples.
The breast cancer imaging company says its customers in the US will get access to Invitae’s comprehensive genetic testing services, within Volpara’s software workflow.
After signing a deal with Invitae, Volpara will integrate Invitae into Volpara’s software workflow to create additional access for women to comprehensive genetic testing services in different clinical settings.
Volpara says its market share in the US is huge, and that at least one Volpara software product is used with over 32% of women who attend screening each year in the country.
The company says its lead drug, RECCE (R327) has shown positive efficacy against Clostridium perfringens and Streptococcus pyogenes – two main strains of bacteria associated with necrotising fasciitis, also known as ‘flesh- eating’ disease.
This is a life-threatening bacterial infection with a mortality rate of up to 80%.
The company says the study has shown that R327 reduces deadly ‘flesh-eating’ bacterial count below the limit og Quantification (BLOQ) within 24 hours, at varying concentrations.
The company has signed an agreement with WEP Clinical for the exclusive development of Named Patient Programmes relating to the supply of its proprietary cannabis products, NanaBis and NanoCBD, to patients in the UK and Europe.
This agreement was the first partnership for Medlab to supply their cannabinoid medications outside of its current Australian Special Access Scheme.
Total Brain (ASX:TTB) is on a trading halt pending further annoucements.